KSHB: Kansas City Doctors Are at Center of Breakthrough Research for Heart Failure Patients

A global 52-week trial found overweight or obese heart failure patients who took a weekly injection of semaglutide, commonly known as Ozempic or Wegovy, saw an improvement in their symptoms — shortness of breath, fatigue, swelling, and inability to exercise.

KSHB talked to Dr. Mikhail Kosiborod, a cardiologist at Saint Luke’s Mid America Heart Institute and the study’s lead investigator, and Nancy Collins, a patient who was enrolled in the study.

Watch the full story below: